Study summary
A genetically engineered gut microbe was designed to break down oxalate
What was tested
A reversibly engrafting gut bacterium engineered with a five-gene pathway to degrade oxalate, a main component of most kidney stones.
What they found
- The strain reduced high urine oxalate in preclinical models.
- Human testing showed controlled colonization of the gut.
What it means
An early step toward treating high-oxalate stone disease with a living drug.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.